Properties | RSD1000 | RSD 1019 | Lidocaine |
---|---|---|---|
a The in vivo profile involved testing the compounds for effectiveness against ischemia-induced arrhythmias in anaesthetized animals as well as testing for effects on blood pressure, heart rate, and ECG. Therapeutic ratios were estimated from the dose-response curves for antiarrhythmic activity versus effects on the ECG and/or blood pressure. | |||
b The in vitro profile was obtained in isolated perfused rat hearts or isolated myocytes. | |||
c The “ischemic” selectivity ratios were calculated from dose response curves for indices of sodium channel blockade obtained at pH 7.4 and 6.4. Larger ratio values represent greater ischemia-selectivity. The data were taken from Bain et al. (17) and Yong et al. (18). | |||
In vivo profilea | |||
Antiarrhythmic ED50 (μmole/kg/min) | 2.5±0.3 | 2.8±0.4 | 5.4±1.8 |
Therapeutic ratio (versus cardiovascular depression) | 10 | 12 | 9 |
Convulsive dose (μmole/kg/min) | 32 | 32 | 32 |
In vitro profileb | |||
Kv4.2 block IC50 (μM) | 6.6±1.4 | ||
Kv1.5 block IC50 (μM) | 2.8±0.1 | 3.6±0.3 | |
Na block IC50 (μM) | 2.9±0.3 | ||
“Ischemic”-selectivityc for ion channel block | 40 | 70 |